Abstract Details

Title The Association between Serum Glucose Level and Disability Progression in Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 130

Objective

Background BACKGROUND: The risk factors predicting the progression of disability in MS remain poorly understood. Vascular comorbidities are associated with disability in MS but whether serum glucose levels are a significant predictor of disability has not been studied.

Design/Methods DESIGN/METHODS: We collected retrospective data from 62 patients (14 men; 21 African American, 41 caucasian), median age 33.5 (range 19-53, mean 34.1 ±SD7.4) years old, median disease duration 4 (range 1-10, mean 4.0±SD1.7) years. EDSS median 2 (range 1-4.5, mean 2.5±SD1.2) and timed walk median 6.7 (range 5.5-11.1) secs. Median glucose levels were 90 (range 71-171, mean 111±SD 34.4) mg/dl. We used Spearman's correlation coefficient to assess univariate correlations and regression on the ranks to control for the potential confounding covariates age, disease duration, gender and race.

Results RESULTS: Glucose levels were highly correlated with EDSS (r=0.73, p<0.0001) and moderately correlated with timed walk (r=0.4, p<0.0004). Disease duration was weakly correlated with EDSS (r=0.3, p=0.04) but not correlated to time walk (r=0.1,p=0.3). Neither race nor gender were significant predictors of EDSS or timed walk using the Wilcoxon test for the analyses. Using regression on the ranked EDSS scores glucose levels remained a significant predictor (F=81.30; df 1,56; p<.0001) of EDSS scores and of 25 feet timed walks (F=14.88; df 1,56; p=0.0003) after adjusting for age, duration, gender and race.

Conclusions CONCLUSIONS: Glucose levels are a strong predictor of disability progression as measured by EDSS and timed walk. Further studies examining this association longitudinally are necessary to prove a causal relation between glucose levels and disability progression. This can open the way for testing some of the multiple interventions used in diabetes as potential MS disease modifying agents.

Authors/Disclosures
Wael Richeh, MD PRESENTER	Dr. Richeh has nothing to disclose.
Amparo Gutierrez, MD, FAAN (Orlando Health)	Dr. Gutierrez has nothing to disclose.
Jesus Lovera, MD (LSUHSC-New Orleans)	Dr. Lovera has nothing to disclose.
Tracy T. Batchelor, MD, MPH (Brigham and Women's Hospital)	Dr. Batchelor has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up To Date, Inc. An immediate family member of Dr. Batchelor has received publishing royalties from a publication relating to health care. Dr. Batchelor has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��